Solubilizing Systems for Parenteral Formulation Development—Small Molecules

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VI)


“Parenteral” is defined1 as “situated or occurring outside the intestine, and especially introduced otherwise than by way of the intestines”—pertaining to essentially any administration route other than enteral. This field is obviously too broad for an adequate focus in one book, let alone one chapter. Many have nonetheless used the term synonymously with injectable drug delivery. We restrict ourselves to this latter usage. This would thus include intravenous, intramuscular, subcutaneous, intrathecal, and subdural injection. In this chapter we discuss the theoretical and practical aspects of solubilizing small molecules for injectable formulation development and will examine the role of surfactants and other excipients in more recent parenteral delivery systems such as liposomes, solid-drug nanoparticles and particulate carriers.


Cloud Point Dispersion Force Leuprolide Acetate Methylprednisolone Acetate Solubilizing System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson AW. A Textbook of Physical Chemistry. Academic Press, New York, NY, 1973, pp. 323–328.Google Scholar
  2. Alexandridis P and Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)- poly(ethylene oxide) Block Copolymer Surfactants in Aqueous Solutions and at Interfaces: Thermodynamics, Structure, Dynamics, and Modeling (Review). Colloids and Surfaces A: Physicochem Eng Aspects 1995; 96: 1–46.CrossRefGoogle Scholar
  3. Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State. Wiley, Hoboken, NJ, 2003, pp. 59–66.Google Scholar
  4. Bobey DG, Russell AD, and Jones CB. Selection of Disodium Edetate as the Optimal Antimicrobial Additive for Use in Propofol Emulsion. Pharm Ther 2001; 11: 335–341.Google Scholar
  5. Breslow R. Hydrophobic Effects on Simple Organic Reactions in Water. Acc Chem Res 1991; 24: 159–164.CrossRefGoogle Scholar
  6. Breslow R. Hydrophobic and Antihydrophobic Effects on Organic Reactions in Aqueous Solution. In: Cramer CJ, Truhlar DG (eds.), Structure and Reactivity in Aqueous Solution: Characterization of Chemical and Biological Systems (ACS Symposium Series). American Chemical Society, Washington DC, 1994, pp. 291–302.Google Scholar
  7. Breslow R and Maitra U. On the Origin of Product Selectivity in Aqueous Diels-Alder Reactions. Tetrahedron Lett 1984; 25: 1239–1240.CrossRefGoogle Scholar
  8. Breslow R and Rideout DC. Hydrophobic Acceleration of Diels-Alder Reactions. J Am Chem Soc 1980; 102: 7817.CrossRefGoogle Scholar
  9. Coico R, Sunshine G, and Benjamini E. Hypersensitivity Reactions: Antibody-mediated (Type II) Cytotoxic Reactions and Immune Complex (Type III) Reactions. In: Immunology, A Short Course (5th Edition). Wiley, Hoboken, NJ, 2003, pp. 215–224.Google Scholar
  10. Cornford EM, Young D, and Paxton JW. Comparison of the Blood-brain Barrier and Liver Penetration of Acridine Antitumor Drugs. Cancer Chemother Pharmacol 1992; 29(6): 439–444.PubMedCrossRefGoogle Scholar
  11. Cramer F and Henglein FM. Einschlussverbindugen der Cyclodextrin mit Gasen. Angew Chem 1956; 68: 649.Google Scholar
  12. Crocker JC and Grier DG. When like charges attract: The Effects of Geometrical Confinement on Long-range Colloidal Interactions. Phys Rev Letters 1996; 77(9): 1897–1900.CrossRefGoogle Scholar
  13. Derjaguin BV and Landau L. Acta Physicochimica (USSR) 1941; 14: 633.Google Scholar
  14. DiMasi JA and Paquette C. The Economics of Follow-on Drug Research and Development Trends in Entry Rates and the Timing of Development. Pharmacoeconomics 2004; 22(Supplement):2: 1–14.PubMedCrossRefGoogle Scholar
  15. Eisenberg D and Kauzmann W. The Structure and Properties of Water, Oxford University Press, Oxford, UK, 1969.Google Scholar
  16. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, and Rodriguez M. Study of Histamine Release Induced by Acute Administration of Antitumor Agents in Dogs. Cancer Chemother Pharmacol 1988; 21: 246–250.PubMedCrossRefGoogle Scholar
  17. Gaballa GA and Neilson GW. The Effect of Pressure on the Structure of Light and Heavy Water. Mol Phys 1983; 50: 97–111.CrossRefGoogle Scholar
  18. Gmehling J, Lohmann J, Jakob A, Li J, and Joh RA. Modified UNIFAC (Dortmund) Model. 3. Revision and Extension. Ind Eng Chem Res 1998; 37: 4876–4882.CrossRefGoogle Scholar
  19. Gorbaty YE and Demianets YN. An X-Ray Study on the Effect of Pressure on the Structure of Liquid Water. Mol Phys 1985; 55: 571–588.CrossRefGoogle Scholar
  20. Hansch C and Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. Wiley, New York, NY, 1979.Google Scholar
  21. Hwang SM, Lee JM, and Lin H. New Group-interaction Parameters of the UNIFAC Model: Aromatic Methoxyl Binaries. Ind Eng Chem Res 2001; 40: 1740–1747.CrossRefGoogle Scholar
  22. Jain N and Yalkowsky SH. Estimation of the Aqueous Solubility I: Application to Organic Nonelectrolytes. J Pharm Sci 2001; 90(2): 234–252.PubMedCrossRefGoogle Scholar
  23. Krishna G, Hodnick WF, Lang W, Lin X, Karra S, Mao J, and Almassian B. Pharmaceutical Development and Manufacturing of a Parenteral Formulation of a Novel Antitumor Agent, VNP40101M. AAPS PharmsciTech 2001; 2 (3), article 14 (accessed June 2006).Google Scholar
  24. Larsen JR and Larsen LS. Clinical Features and Management of Poisoning Due to Phenytoin. Med Toxicol Adverse Drug Exp 1989; 4(1): 229–245.PubMedGoogle Scholar
  25. Lee RW, Shaw JM, McShane J, and Wood RW. Particle Size Reduction. In: Liu R (ed.), Water-insoluble drug formulation. Interpharm, Denver, CO, 2000, p. 478.Google Scholar
  26. Lee RW, Shaw JM, McShane J, and Wood RW. Particle Size Reduction. In: Liu R (ed.), Water-insoluble drug formulation. Interpharm, Denver, CO, 2000, pp. 487–488.Google Scholar
  27. Leo A. Calculating Log Poct From Structures. Chem Rev 1993; 93: 1281–1306.CrossRefGoogle Scholar
  28. Leo A, Hansch C, and Elkins D. Partition Coefficients and Their Uses. Chem Rev 1971; 71: 525–616.CrossRefGoogle Scholar
  29. Lipinski CA. Drug-like Properties and the Causes of Poor Solubility and Poor Permeability. J Pharmacol Toxicol Methods 2000; 44: 235–249.PubMedCrossRefGoogle Scholar
  30. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Del Rev 1997; 23: 3–25.CrossRefGoogle Scholar
  31. Lohmann J, Joh R, and Gmehling J. From UNIFAC to Modified UNIFAC (Dortmund). Ind Eng Chem Res 2001; 40: 957–964.CrossRefGoogle Scholar
  32. Lynden-Bell RM, Rasaiah JC, and Noworyta JP. Using Simulation to Study Solvation in Water. Pure Appl Chem 2001; 73(11): 1721–1731.Google Scholar
  33. MacNeil JS. Abraxane Comes Through with Proof of Superiority, Scientific Endorsements. NanoBioTech News 2003; 1(19): 1–5.Google Scholar
  34. McLeish MJ. Thiopental Sodium. In: Brittain HG (ed), Analytical Profiles of Drug Substances and Excipients (Vol. 21). Academic Press, New York, NY, 1992, p. 540.Google Scholar
  35. Mounier P, Laroche D, Divanon F, Mosquet B, Vergnaud MC, Esse-Comlan A, Piquet MA, and Bricard H. Anaphylactoid Reactions to an Injectable Solution of a Cremophor-containing Solution of Multivitamins. Therapie 1995; 50: 571–573.PubMedGoogle Scholar
  36. Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, and Grolleau R. A Randomized Hemodynamic Comparison of Intravenous Amiodarone with and without Tween-80. Eur Heart J 1998; 9: 142–148.Google Scholar
  37. Ornektekin S, Paksoy H, and Demirel Y. The Performance of UNIFAC and Related Group Contribution Models Part II. Prediction of Henry's Law Constant. Thermochimica Acta 1996; 287: 251–259.CrossRefGoogle Scholar
  38. Rytting E, Lentz KA, Chen X-Q, Qian F, and Venkatesh S. Aqueous and Cosolvent Solubility Data for Drug-like Compounds. AAPS Journal 2005; 7(1) Article 10.CrossRefGoogle Scholar
  39. Sciortino F, Geiger A, and Stanley HE. Network Defects and Molecular Mobility in Liquid Water.J Chem Phys 1992; 96: 3857–3865.CrossRefGoogle Scholar
  40. Sweetana S and Akers MJ. Solubility Principles and Practices for Parenteral Drug Dosage Form Development. PDA J Pharm Sci Tech 1996; 50(2): 330–342.Google Scholar
  41. Tanford C. The Hydrophobic Effect: Formation of Micelles and Biological Membranes, 2nd ed. Wiley, New York, NY, 1980.Google Scholar
  42. Theis JG, Liau-Chu M, Chan HS, Doyle J, Greenberg ML, and Koren G. Anaphylactoid Reactions in Children Receiving High-dose Intravenous Cyclosporine for Reversal of Tumor Resistance: The Causative Role of Improper Dissolution of Cremophor EL. J Clin Oncol 1995; 13: 2508–2516.PubMedGoogle Scholar
  43. Verwey EJ and Overbeek JTG. Theory of the Stability of Lyophobic Colloids. Elsevier, Amsterdam, 1948.Google Scholar
  44. Volcheck GW and Van Dellen RG. Anaphylaxis to Intravenous Cyclosporine and Tolerance to Oral Cyclosporine: Case Report and Review. Ann Allergy Asthma Immunol 1998; 80: 159–163.PubMedCrossRefGoogle Scholar
  45. Wang R, Fu Y, and Lai L. A New Atom-additive Method for Calculating Partition Coefficients.J Chem Inf Comput Sci 1997; 37: 615–621.CrossRefGoogle Scholar
  46. Wheless JW. Pediatric Use of Intravenous and Intramuscular Phenytoin: Lessons Learned.J Child Neurol 1998; 13: S11–S14, discussion S30–S32.PubMedCrossRefGoogle Scholar
  47. Wojcik JF and Rohrbach RP. Small Anion Binding to Cycloamylose. Equilibrium Constants. J Phys Chem 1975; 79: 2251.CrossRefGoogle Scholar
  48. Wu AY, Whalley E, and Dolling G. Neutron Diffraction of Heavy Water to 15.6 Kbar. Mol Phys 1982; 47: 603–628.CrossRefGoogle Scholar
  49. Yalkowsky SW and He Y. Handbook of Aqueous Solubility. CRC Press, Boca Raton, FL, 2003, p. 764.Google Scholar
  50. Yalkowsky SW and He Y. Handbook of Aqueous Solubility. CRC Press, Boca Raton, FL, 2003, p. 998.Google Scholar

Copyright information

© Springer 2007

Authors and Affiliations

    • 1
  1. 1.BioPharma SolutionsBaxter Healthcare CorporationRound LakeUSA

Personalised recommendations